Carsten Brunn, Selecta Biosciences CEO
March 10, 2022 02:10 PM EST
R&D
FDA+

FDA lifts a clin­i­cal hold on Se­lec­ta gene ther­a­py af­ter an­oth­er de­lay ham­pers R&D plans

John Carroll

Editor & Founder

Three months af­ter Se­lec­ta Bio­Sciences got word that the FDA had slapped a clin­i­cal hold on its Phase I/II study of methyl­malonic acidemia drug SEL …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times